Staphylococcus aureus Bacteremia- Pipeline Insight, 2024

Staphylococcus aureus Bacteremia- Pipeline Insight, 2024

DelveInsight’s, “Staphylococcus aureus Bacteremia- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Staphylococcus aureus Bacteremia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Staphylococcus aureus Bacteremia: Understanding

Staphylococcus aureus Bacteremia: Overview

Staphylococcus aureus is an important cause of bacteremia, and S. aureus bacteremia constitutes a serious condition with high morbidity and mortality, secondary to multiple complications including infective endocarditis and embolization. The incidence of bacteremia with S. aureus is increasing with more frequent use of medications that lower immune system response, and with the utilization of more invasive medical procedures. Staphylococcus aureus is a Gram‐positive staphylococci that can exist commensally with humans as a colonizer but can also exist as a pathogen. It is a major pathogen in bacteremia whether community acquired or hospital acquired. It has proven its versatility by continuing to be an important infectious pathogen that has contributed to increasing morbidity and mortality of patients over the years. Despite the advances in antibiotic therapy targeting this pathogen, S. aureus remains a multipotent organism that causes infection using toxin production and nontoxin‐mediated pathways. This organism causes a wide array of infections, from a simple skin infection to more dangerous situations such as bacteremia, endocarditis, pneumonia, bone and joint infections, and many others that may jeopardize the life of the patient. Patients with S. aureus bacteremia can be at risk for many complications that may increase morbidity, with mortality rates of 20–40% that have been described. The higher the level of resistance, the higher the mortality rates. This is why methicillin‐resistant S. aureus (MRSA) is expected to have a higher morbidity/morality, longer hospital stays, and higher health care costs when compared with methicillin‐sensitive S. aureus (MSSA) bacteremia. Several factors associated with an increased risk of developing SAB have been identified, including previous MRSA infection or colonization, skin ulcers or cellulitis at hospital admission, presence of central venous catheters, urinary catheter insertion, surgical site infection, injection drug use, presence of immunosuppressive conditions, use of corticosteroids, and liver disease. Numerous guidelines for the prevention and management of SAB exist, but these are not uniform in their recommendations. Many cases of SAB originate from colonization of the nasal mucosa; thus, elimination of nasal carriage by locally applied or systemic antibiotics is a useful prevention strategy. Early and aggressive antibiotic therapy and the removal of intravascular devices are important for optimal management.

""Staphylococcus aureus Bacteremia- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Staphylococcus aureus Bacteremia pipeline landscape is provided which includes the disease overview and Staphylococcus aureus Bacteremia treatment guidelines. The assessment part of the report embraces, in depth Staphylococcus aureus Bacteremia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Staphylococcus aureus Bacteremia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Staphylococcus aureus Bacteremia R&D. The therapies under development are focused on novel approaches to treat/improve Staphylococcus aureus Bacteremia.

Staphylococcus aureus Bacteremia Emerging Drugs Chapters

This segment of the Staphylococcus aureus Bacteremia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Staphylococcus aureus Bacteremia Emerging Drugs

• Exebacase: ContraFect

Exebacase (CF-301) is a lysin with potent activity against Staphylococcus aureus (""Staph aureus""). Exebacase has the potential to be the first-in-class of a new treatment for patients with Staph aureus bacteremia. Exebacase targets a highly conserved region of the cell wall that is vital to bacteria, thus making resistance less likely to develop. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Staphylococcus aureus Bacteremia.

• AP-SA02: Armata Pharmaceuticals

AP-SA02 is a novel biologic product candidate comprising natural lytic phages that target the problematic pathogen, Staphylococcus aureus, and offers robust therapeutic attributes, including: Potent antimicrobial activity against approximately 95% of S. aureus clinical isolates tested, including drug-resistant isolates (MRSA: methicillin-resistant S. aureus and VRSA: vancomycin-resistant S. aureus);Unique mechanism of action offers synergistic or additive benefit with standard of care antibiotics; Component phages are stable and retain infectivity after exposure to relevant biological fluids; Penetrates pre-existing S. aureus biofilms. AP-SA02 is currently manufactured under cGMP at our production facility in Marina del Rey, California to support the required regulatory filing(s) for clinical studies in the U.S. and ex-U.S. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Staphylococcus aureus Bacteremia.

Further product details are provided in the report……..

Staphylococcus aureus Bacteremia: Therapeutic Assessment

This segment of the report provides insights about the different Staphylococcus aureus Bacteremia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Staphylococcus aureus Bacteremia

There are approx. 10+ key companies which are developing the therapies for Staphylococcus aureus Bacteremia. The companies which have their Staphylococcus aureus Bacteremia drug candidates in the most advanced stage, i.e. Phase III, ContraFect.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Staphylococcus aureus Bacteremia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Staphylococcus aureus Bacteremia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Staphylococcus aureus Bacteremia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Staphylococcus aureus Bacteremia drugs.

Staphylococcus aureus Bacteremia Report Insights

• Staphylococcus aureus Bacteremia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Staphylococcus aureus Bacteremia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Staphylococcus aureus Bacteremia drugs?
• How many Staphylococcus aureus Bacteremia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Staphylococcus aureus Bacteremia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Staphylococcus aureus Bacteremia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Staphylococcus aureus Bacteremia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• ContraFect
• Armata Pharmaceuticals
• iNtRON Biotechnology
• Durata Therapeutics
• Cipher Pharmaceuticals
• XBiotech
• Basilea Pharmaceutica
• Genentech

Key Products

• Exebacase
• AP-SA02
• LSVT-1701
• Dalbavancin
• 514G3
• Ceftobiprole medocaril
• DSTA4637S